Hans-Beat Gürtler

The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates.

Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland.

The Basel Chamber of Commerce is an organization that advocates for the interests of the industry and promotes the region as the most important logistics hub in Switzerland. The non-profit company is based in Basel, Switzerland. The company also has a Swiss School for International Business.

Elanco Tiergesundheit AG manufactures animal vaccines. The firm provides pet health, livestock and Bioprotection products. The company's products include Atopica, Capstar, Deramaxx, Fortekor, Interceptor, Milbemax, Parc-tic and Sentinel. It is headquartered in Basel, Switzerland.

ErfindungsVerwertung AG engages in the provision of seed capital as well as consulting and market research services to startup companies in the field of life sciences. It offers project and business plan reviews, financial planning, business set-up, coaching, and assistance to find venture capital. The firm supports life sciences researchers, initiators of university projects, developers, and inventors in the field of drug development, medical technology, diagnostics, biomedicine, and nanotechnology. The company was founded in 1996 and is headquartered in Basel, Switzerland.